Screener
Nektar Therapeutics NKTR Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 187,055 | 190,574 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at March 31, 2026 or December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 390,000,000 shares authorized; 29,472,092 shares and 20,378,832 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 2 |
| Capital in excess of par value | 4,382,437 | 3,850,099 |
| Accumulated other comprehensive income (loss) | (1,034) | 17 |
| Accumulated deficit | (3,805,190) | (3,760,286) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's preferred stock, shares authorized?
- Nektar Therapeutics (NKTR) reported preferred stock, shares authorized of $10M in Q1 2026.
- How has Nektar Therapeutics's preferred stock, shares authorized changed year-over-year?
- Nektar Therapeutics's preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
- What is the long-term trend for Nektar Therapeutics's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Nektar Therapeutics's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
Ask your AI about Nektar Therapeutics's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude